[{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Hydroconchinine","moa":"CD7","graph1":"Oncology","graph2":"Phase II","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hebei Senlang Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hebei Senlang Biotechnology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Hydroconchinine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hebei Senlang Biotechnology

                          Country arrow
                          Biotech Showcase
                          Not Confirmed

                          Hebei Senlang Biotechnology

                          Country arrow
                          Biotech Showcase
                          Not Confirmed

                          Details : S101 is a cell & gene therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          November 24, 2025

                          Lead Product(s) : Hydroconchinine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank